Somnomed Ltd
ASX:SOM

Watchlist Manager
Somnomed Ltd Logo
Somnomed Ltd
ASX:SOM
Watchlist
Price: 0.595 AUD 1.71% Market Closed
Market Cap: 128.6m AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+37%
Revenue
Forecast
+12%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

SOM Price Targets Summary
Somnomed Ltd

Wall Street analysts forecast SOM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SOM is 0.816 AUD with a low forecast of 0.808 AUD and a high forecast of 0.84 AUD.

SOM Lowest Forecast
Wall Street Target
0.808 AUD
36% Upside
SOM Average Forecast
Wall Street Target
0.816 AUD
37% Upside
SOM Highest Forecast
Wall Street Target
0.84 AUD
41% Upside
Lowest
Price Target
0.808 AUD
36% Upside
Average
Price Target
0.816 AUD
37% Upside
Highest
Price Target
0.84 AUD
41% Upside
Somnomed Ltd Competitors:
Price Targets
BIM
Biomerieux SA
9% Upside
E
NVST
Envista Holdings Corp
10% Upside
IDXX
IDEXX Laboratories Inc
1% Upside
RMD
Resmed Inc
8% Upside
BIM
Biomerieux SA
9% Upside
E
NVST
Envista Holdings Corp
10% Upside
IDXX
IDEXX Laboratories Inc
1% Upside
RMD
Resmed Inc
8% Upside
2190
Zylox-Tonbridge Medical Technology Co Ltd
6% Upside
2235
MicroTech Medical Hangzhou Co Ltd
7% Downside
ABT
Abbott Laboratories
8% Upside
O
OPTOMED
Optomed Oyj
24% Upside

Revenue
Forecast

Revenue Estimate
Somnomed Ltd

For the last 8 years the compound annual growth rate for Somnomed Ltd's revenue is 10%. The projected CAGR for the next 3 years is 12%.

10%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Somnomed Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Somnomed Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
What are analyst estimates?

See Also

Summary
SOM intrinsic value, competitors valuation, and company profile.
DCF Valuation
SOM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SOM stock valuation using valuation multiples.
Wall Street Estimates
SOM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SOM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SOM's stock price target?
Price Target
0.816 AUD

According to Wall Street analysts, the average 1-year price target for SOM is 0.816 AUD with a low forecast of 0.808 AUD and a high forecast of 0.84 AUD.

What is Somnomed Ltd's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Somnomed Ltd's revenue is 10%. The projected CAGR for the next 3 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.